Can the commercial sector capitalize on the merger of high-throughput technology and natural products? Cormac Sheridan investigates.
References
Davies, J. & Ryan, K.S. ACS Chem. Biol. 7, 252–259 (2012).
Zazopoulos, E. et al. Nat. Biotechnol. 21, 187–190 (2003).
McAlpine, J.B. et al. J. Nat. Prod. 68, 493–496 (2005).
Banskota, A.H. et al. J. Antibiot. (Tokyo) 59, 168–176 (2006).
Banskota, A.H. et al. J. Antibiot. (Tokyo) 59, 533–542 (2006).
Moss, S.J. et al. Med. Chem. Commun. doi:10.1039/C1MD00227A (2012).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sheridan, C. Recasting natural product research. Nat Biotechnol 30, 385–387 (2012). https://doi.org/10.1038/nbt.2208
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2208
- Springer Nature America, Inc.
This article is cited by
-
Establishing a genomic database for the medicinal plants in the Brazilian Pharmacopoeia
Chinese Medicine (2021)
-
Nature Biotechnology's academic spinouts of 2017
Nature Biotechnology (2018)
-
The 160K Natural Organism Library, a unique resource for natural products research
Nature Biotechnology (2018)
-
The pharmaceutical industry and natural products: historical status and new trends
Phytochemistry Reviews (2015)
-
Antibiotic resistance–mediated isolation of scaffold-specific natural product producers
Nature Protocols (2014)